These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21892895)

  • 21. Pramipexole: in restless legs syndrome.
    McCormack PL; Siddiqui MA
    CNS Drugs; 2007; 21(5):429-37; discussion 438-40. PubMed ID: 17447832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The acute effect of a low dosage of pramipexole on severe idiopathic restless legs syndrome: an open-label trial.
    Merlino G; Dolso P; Canesin R; Cancelli I; Valente M; Gigli GL
    Neuropsychobiology; 2006; 54(3):195-200. PubMed ID: 17314491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease.
    Schapira AH; Barone P; Hauser RA; Mizuno Y; Rascol O; Busse M; Debieuvre C; Fraessdorf M; Poewe W
    Eur J Neurol; 2013 Jan; 20(1):180-7. PubMed ID: 22845710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of pramipexole in the management of Parkinson's disease.
    Antonini A; Barone P; Ceravolo R; Fabbrini G; Tinazzi M; Abbruzzese G
    CNS Drugs; 2010 Oct; 24(10):829-41. PubMed ID: 20839895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pramipexole in the treatment of restless legs syndrome: a follow-up study.
    Montplaisir J; Denesle R; Petit D
    Eur J Neurol; 2000 May; 7 Suppl 1():27-31. PubMed ID: 11054156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements.
    Manconi M; Ferri R; Zucconi M; Oldani A; Fantini ML; Castronovo V; Ferini-Strambi L
    Sleep Med; 2007 Aug; 8(5):491-7. PubMed ID: 17512780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease.
    Rascol O; Barone P; Hauser RA; Mizuno Y; Poewe W; Schapira AH; Salin L; Sohr M; Debieuvre C;
    Mov Disord; 2010 Oct; 25(14):2326-32. PubMed ID: 20669265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The long-term effects of the dopamine agonist pramipexole in a proposed restless legs syndrome animal model.
    Luo F; Li C; Ondo WG; Xu P; Xie W; Le W
    Sleep Med; 2011 Jan; 12(1):41-6. PubMed ID: 21044864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transdermal delivery of dopamine receptor agonists.
    Reichmann H
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S93-6. PubMed ID: 20123566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
    Costa A; Peppe A; Dell'Agnello G; Caltagirone C; Carlesimo GA
    Neuropsychologia; 2009 Apr; 47(5):1374-81. PubMed ID: 19428401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pramipexole extended release: in Parkinson's disease.
    Chwieduk CM; Curran MP
    CNS Drugs; 2010 Apr; 24(4):327-36. PubMed ID: 20297857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease.
    Brodsky MA; Park BS; Nutt JG
    Arch Neurol; 2010 Jan; 67(1):27-32. PubMed ID: 20065126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
    Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
    Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levodopa delivery systems: advancements in delivery of the gold standard.
    Ngwuluka N; Pillay V; Du Toit LC; Ndesendo V; Choonara Y; Modi G; Naidoo D
    Expert Opin Drug Deliv; 2010 Feb; 7(2):203-24. PubMed ID: 20095943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Critical review of ropinirole and pramipexole - putative dopamine D(3)-receptor selective agonists - for the treatment of RLS.
    Varga LI; Ako-Agugua N; Colasante J; Hertweck L; Houser T; Smith J; Watty AA; Nagar S; Raffa RB
    J Clin Pharm Ther; 2009 Oct; 34(5):493-505. PubMed ID: 19744006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of two different dopamine agonists in the management of Parkinson's disease.
    Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
    Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease.
    Hauser RA; Schapira AH; Barone P; Mizuno Y; Rascol O; Busse M; Debieuvre C; Fraessdorf M; Poewe W;
    Eur J Neurol; 2014 May; 21(5):736-43. PubMed ID: 24834511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of pramipexole and its clinical utility in Parkinson's disease.
    Biglan KM; Holloway RG
    Expert Opin Pharmacother; 2002 Feb; 3(2):197-210. PubMed ID: 11829733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Classics in Chemical Neuroscience: Pramipexole.
    Wilson SM; Wurst MG; Whatley MF; Daniels RN
    ACS Chem Neurosci; 2020 Sep; 11(17):2506-2512. PubMed ID: 32786316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.